Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @AmitR_nyc
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AmitR_nyc
-
Amit Rakhit proslijedio/la je Tweet
#Ovid would like to wish the#raredisease community a#HappyHolidays!pic.twitter.com/3Titsh5pRbHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
A message from
@jmaxlevin to the#AngelmanSyndrome patients, families, and community that we serve. On behalf of every employee at#Ovid, we wish you a joyful holiday season and a very Happy New Year.pic.twitter.com/apGUH7uO2X
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
An
#Angelmansyndrome diagnosis can be extremely impactful on a family, changing their future. Hear how one family is embracing each day with hope, thanks to help from their friends and local community.https://bit.ly/2vADyDpHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
We were glad to sponsor the Patient-Focused Drug Development meeting on developmental & epileptic encephalopathies including
#LennoxGastaut hosted by@LGS_Foundation last month. To hear insights from caregivers or to watch the moving opening video, visit https://www.lgsfoundation.org/pfdd .Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
For people living with
#Angelmansyndrome,#hyperactivity, and#anxiety are very common. Extreme emotions and over-excitement can be a struggle to manage.#Ovid is developing new medicines for families living with Angelman syndrome. We’re listening.https://bit.ly/2LZBLiRHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
We support the efforts of 25+ national & international organizations in recognizing Infantile Spasms Awareness Week. Please retweet to help raise awareness among families as well as medical professionals. Learn more about
#infantilespasms at http://ISweek.org .#ISAW2019Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
Thank you to
@CDKL5USA & The Loulou Foundation for organizing a meeting to enable families to share their perspective on the impact of#CDKL5 Deficiency on daily life with researchers & officials at@US_FDA. Watch the video at https://cdkl5.com/pfdd/ .#CDKL5PFDDHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
In a video by
@GlobalGenes,@lukebrosen, VP of Patient Engagement & Government Affairs, shares the importance of infusing what matters most to families in every element of the discovery & development of new treatments for#rarediseases.https://globalgenes.org/2019/11/04/next-luke-rosen-kif1a-org-discusses-the-future-of-rare-disease/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
That wraps up our
#Twitterchat! If you’d like to ask a question, reply below and we’ll try to follow-up.#Angelmansyndrome#FASTsummit2019 (@AmitR_nyc)Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
We’ve gotten a few questions regarding locations of our studies, especially regarding NEPTUNE and specifically regarding international locations. At this time, sites in the US are San Diego (CA), Tacoma (WA), Media (PA) and Phoenix (AZ). (
@AmitR_nyc)Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
In that study, we saw an improvement in overall global functioning as measured by a specific scale called the CGI-I. This helped inform the design of our Phase 3 NEPTUNE study, after discussions with the FDA. (
@AmitR_nyc)Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
Now, what does that mean? OV101 had no significant safety and tolerability concerns and had improvements in several areas of an individual’s functioning. (
@AmitR_nyc)Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
The Study met safety and tolerability endpoints as well as achieving a statistically significant (p= 0.0006) efficacy endpoint in the study. (
@AmitR_nyc)Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
Let’s talk about STARS, the first industry-sponsored, international, randomized, double-blind, placebo-controlled
#clinicalstudy in adults and adolescents with#Angelmansyndrome. (@AmitR_nyc)Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
We’re excited that enrollment is open for all ages (4 – 12 years old) and we look forward to the results from the Phase 3 NEPTUNE
#clinicalstudy in mid-2020. (@AmitR_nyc)Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
Additionally, the independent data monitoring committee’s review of the safety and dosing information in the Phase 3 NEPTUNE study corroborates our
#pediatric dose modeling that guided the dosing paradigm in the#clinicalstudy. (@AmitR_nyc)Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
After a predetermined review by the independent data monitoring committee (IDMC) of the NEPTUNE safety and PK information. The IDMC recommended opening enrollment to the younger age cohort (ages 4-8).
#Angelmansyndrome#FragileX (@AmitR_nyc)Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
At
#FastSummit2019, I announced progress in the ongoing clinical development of OV101, our investigational therapy for#Angelmansyndrome and#FragileX syndrome. (@AmitR_nyc)Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
Hello everyone. Happy to take over Ovid’s Twitter handle for a quick
#twitterchat to discuss further some of the information I presented at@cureangelman last Friday.#Fastsummit2019#Angelmansyndrome (@AmitR_nyc)Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amit Rakhit proslijedio/la je Tweet
Let me take this opportunity to thank
@cureangelman for having us. Our team was able to meet with quite a few patients and caregivers. We always look forward to opportunities to speak with the#Angelmansyndrome community.#Fastsummit2019 (@AmitR_nyc)Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.